Literature DB >> 18523084

Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome.

J M Ruiz-Moreno1, P Amat, J A Montero, F Lugo.   

Abstract

AIMS: To report the visual outcome in a series of eyes with myopic choroidal neovascularisation treated by photodynamic therapy (PDT) followed during 48 months.
METHODS: Prospective, consecutive, non-randomised interventional case series. Thirty-nine eyes from 36 highly myopic patients treated by PDT were evaluated. Best corrected visual acuity (BCVA) and fluorescein angiography were performed every 3 months. Multiple regression analysis was used to analyse changes in BCVA in relationship with initial BCVA, spherical equivalent, age, diameter of CNV and chorioretinal atrophy.
RESULTS: Mean initial BCVA was 9.0 Early Treatment Diabetic Retinopathy Study lines (SD 4.3). BCVA was 10.4 lines (3.6) at month 12, 9.7 lines (SD 3.9) at month 24, 9.6 lines (SD 3.8) at month 36 and 9.6 lines (SD 4.2) at month 48. BCVA improvement was associated with initial BCVA (p<0.002), lesion diameter (p<0.04) and age (p<0.04) (multiple regression analysis).
CONCLUSIONS: Our results suggest a better visual outcome for those eyes with better initial BCVA and larger lesions in younger patients treated by PDT. The poorer results for elderly patients with lower initial BCVA might lead us to consider other therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523084     DOI: 10.1136/bjo.2007.132795

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization.

Authors:  C S Tan; M C Chew; T H Lim
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

2.  A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Authors:  Alfredo Pece; Paolo Milani; Carla Monteleone; Costantino John Trombetta; Giuseppe De Crecchio; Giuseppe Fasolino; Domenica Matranga; Salvatore Cillino; Maria Vadalà
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-13       Impact factor: 3.117

3.  Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome.

Authors:  Jose M Ruiz-Moreno; Javier A Montero
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-10       Impact factor: 3.117

4.  Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization.

Authors:  Jane Zea-Chin Kuo; Frank Shih-Chang Ong; Ling Yeung; Wei-Chi Wu; Yen-Po Chen; Nan-Kai Wang; Chi-Chun Lai
Journal:  Retina       Date:  2011-10       Impact factor: 4.256

5.  Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.

Authors:  Akio Oishi; Kenji Yamashiro; Akitaka Tsujikawa; Sotaro Ooto; Hiroshi Tamura; Isao Nakata; Masahiro Miyake; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-19       Impact factor: 3.117

Review 6.  Photodynamic therapy: current role in the treatment of chorioretinal conditions.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

7.  Low-fluence-rate photodynamic therapy to treat subfoveal choroidal neovascularization in pathological myopia. A study of efficacy and safety.

Authors:  Gianluca Besozzi; Luigi Sborgia; Claudio Furino; Nicola Cardascia; Rosanna Dammacco; Giancarlo Sborgia; Andrea Palma Modoni; Francesco Boscia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04       Impact factor: 3.117

Review 8.  Current and emerging treatment options for myopic choroidal neovascularization.

Authors:  Leila El Matri; Ahmed Chebil; Fedra Kort
Journal:  Clin Ophthalmol       Date:  2015-04-24

9.  Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization.

Authors:  Luca Di Antonio; Lisa Toto; Alessandra Mastropasqua; Lorenza Brescia; Emanuele Erroi; Alessia Lamolinara; Marta Di Nicola; Leonardo Mastropasqua
Journal:  Sci Rep       Date:  2018-10-23       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.